MEN2501 for Platinum-Resistant Ovarian Cancer
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Stemline Therapeutics, Inc. · Industry
This trial is looking for adults with certain types of ovarian cancer who want to try a new treatment called MEN2501. Participants will receive this treatment and help researchers learn about its safety and effects.
You may be able to join if
- I have high-grade serous ovarian cancer.
- I have primary peritoneal cancer.
- I have fallopian tube cancer.
You may not be able to join if
- I have primary platinum-refractory disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Loading trial locations…
Stemline Trials
1-877-332-7961
cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com
CONTACT